MannKind Stock Hits New 52-Week Low (MNKD)

NEW YORK ( TheStreet) -- MannKind Corporation (Nasdaq: MNKD) hit a new 52-week low Thursday as it is currently trading at $1.96, below its previous 52-week low of $1.97 with 764,617 shares traded as of 10:15 a.m. ET. Average volume has been 1.6 million shares over the past 30 days.

MannKind has a market cap of $359.1 million and is part of the health care sector and drugs industry. Shares are down 17.6% year to date as of the close of trading on Wednesday.

MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States, Europe, and Asia.

TheStreet Ratings rates MannKind as a sell. The company's weaknesses can be seen in multiple areas, such as its generally disappointing historical performance in the stock itself, poor profit margins and weak operating cash flow. You can view the full MannKind Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.

If you liked this article you might like

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Mannkind in Free Fall After Changes to Insulin Product, Sales Force

Mannkind Stock Drops Following Changes to Its Insulin Product

Laser-Maker Cynosure Leads Biotech Movers Ahead of Market Open

Insulin Drug Offers Hope for MannKind